Overview

Llama Antibody, Rotavirus Diarrhoea, Children

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that : oral administration of VHH batch 203027 will be - safe and tolerable for healthy Bangladeshi humans of all age groups (Part I) - effective in reducing severity of diarrhoea in children with proven rotavirus infection (Part II). This entry only covers Part II.
Phase:
Phase 2
Details
Lead Sponsor:
International Centre for Diarrhoeal Disease Research, Bangladesh
Collaborator:
Unilever Nederland Holdings
Treatments:
Antibodies